Medistem’s planned clinical trials are centered on therapies using the Endometrial Regerative Cell (ERC). Because these are “universal donor” cells that are not rejected by the recipients’ body, a single source of cells can be used to treat all patients suffering from a particular condition. This provides the patient with a safe, controlled, and cost-effective cellular-based treatment which can be easily delivered at the point of care by a doctor. Medistem anticipates developing a master cell bank, subjected to rigorous and strict quality control procedures, to serve as the source of its products.
Medistem is currently focused on developing products to treat the following conditions:
- Critical Limb Ischemia (1.1 million people in USA) – a severe obstruction of the arteries which seriously decreases bloodflow to the extremities (hands, feet and legs) and has progressed to the point of severe pain and even skin ulcers or sores. Current approved therapies for limb ischemia are limited to revascularization surgery and amputation. Medistem’s product candidates are currently in late preclinical development with animal efficacy studies completed (add link to publication of studies)
- Ischemic Heart Disease (18.5 million people in USA) – a disease characterized by reduced blood supply to the heart muscle, usually due to coronary artery disease. Medistem’s product candidates have been demonstrated to differentiate into cardiac tissue, as well as grow new blood vessels. Successfully clinical entry of Medistem’s products for critical limb ischemia will negate the need for duplicating clinical safety studues and permit rapid entry to Phase IIb clinical trials.